Pharma stalwarts demystify COVID-19 impact on industry
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
The company will be holding 26% of the share capital in each of the solar power generating companies.
The company will review FDA's response and decide on appropriate next steps soon.
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
DHL and other logistics companies were already transporting pharmaceutical products at minus 70°C in Schaumaplast boxes packed with dry ice before the coronavirus pandemic
India business grew 11.8% YoY vs mid-single digit industry growth.
The jump in profit is due to the better performance of the API business.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Subscribe To Our Newsletter & Stay Updated